Federica Ramani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Federica Ramani has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
Davide Stolfo
Cardiothoracic Department Azienda Sanitaria Universitaria Integrata di Trieste and University of Trieste Italy
14 shared publications- Giulia Barbati
University of Trieste
14 shared publications Marta Gigli
Cardiothoracic Department Azienda Sanitaria Universitaria Integrata di Trieste and University of Trieste Italy
12 shared publicationsBruno Pinamonti
S.C. Cardiologia, Dipartimento Cardiotoracovascolare, Centro per la Diagnosi e Cura delle Cardiomiopatie, Azienda Sanitaria Universitaria Giuliano Isontina e Università degli Studi di Trieste
11 shared publications- Gianfranco Sinagra
Cardiovascular Department, Azienda Sanitaria Universitaria Integrata, 34149 Trieste, Italy
10 shared publications Gianfranco Sinagra
Cardiothoracic Department Azienda Sanitaria Universitaria Integrata di Trieste and University of Trieste Italy
9 shared publications
Latest Publications
- 1 December 2020
- Published by Il Pensiero Scientifico Editore in Giornale Italiano di Cardiologia
- Vol. 21 (12) , 935-953
Inquadramento e gestione delle cardiomiopatie: il protocollo della Cardiologia di Trieste
Le cardiomiopatie sono malattie primitive del miocardio con importante componente genetica. Esordiscono in genere tra i 30 e i 50 anni e sono le più comuni cause di morte improvvisa e scompenso cardiaco nel giovane adulto. Le principali cardiomiopatie riscontrate nella pratica clinica sono la cardiomiopatia dilatativa, la cardiomiopatia aritmogena e la cardiomiopatia ipertrofica. Nonostante il progresso delle conoscenze degli ultimi anni, reso possibile in particolare dalla diffusione di tecniche di sequenziamento genico di nuova generazione e da metodiche di imaging avanzate, la diagnosi, l’inquadramento eziologico e la gestione delle cardiomiopatie rimangono complessi e per alcuni aspetti controversi. Questa rassegna ha lo scopo di proporre delle flow-chart operative, integrando le più recenti evidenze scientifiche con i protocolli gestionali del Dipartimento Cardiotoracovascolare dell’Ospedale di Trieste, uno dei Centri di riferimento nazionali per le cardiomiopatie e lo scompenso cardiaco con esperienza trentennale in tale ambito.
- 1 December 2020
- Published by Il Pensiero Scientifico Editore in Giornale Italiano di Cardiologia
- Vol. 21 (12) , 935-953
Inquadramento e gestione delle cardiomiopatie: il protocollo della Cardiologia di Trieste
Le cardiomiopatie sono malattie primitive del miocardio con importante componente genetica. Esordiscono in genere tra i 30 e i 50 anni e sono le più comuni cause di morte improvvisa e scompenso cardiaco nel giovane adulto. Le principali cardiomiopatie riscontrate nella pratica clinica sono la cardiomiopatia dilatativa, la cardiomiopatia aritmogena e la cardiomiopatia ipertrofica. Nonostante il progresso delle conoscenze degli ultimi anni, reso possibile in particolare dalla diffusione di tecniche di sequenziamento genico di nuova generazione e da metodiche di imaging avanzate, la diagnosi, l’inquadramento eziologico e la gestione delle cardiomiopatie rimangono complessi e per alcuni aspetti controversi. Questa rassegna ha lo scopo di proporre delle flow-chart operative, integrando le più recenti evidenze scientifiche con i protocolli gestionali del Dipartimento Cardiotoracovascolare dell’Ospedale di Trieste, uno dei Centri di riferimento nazionali per le cardiomiopatie e lo scompenso cardiaco con esperienza trentennale in tale ambito.
- 1 January 2020
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 36 (1) , 37-44
Sex Differences in the Long-term Prognosis of Dilated Cardiomyopathy
- 1 January 2020
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 36 (1) , 37-44
Sex Differences in the Long-term Prognosis of Dilated Cardiomyopathy
- Open Access
- 3 September 2019
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 8 (17) , e010705
Dilated Cardiomyopathy With Mid‐Range Ejection Fraction at Diagnosis: Characterization and Natural History
Background: Limited data are available on mid‐range ejection fraction (mr EF ) patients with dilated cardiomyopathy. We sought to define the characteristics, evolution, and long‐term prognosis of dilated cardiomyopathy patients with mr EF at diagnosis. Methods and Results: We analyzed all dilated cardiomyopathy patients consecutively evaluated in the Trieste Heart Muscle Disease Registry from 1988 to 2013. mr EF and reduced ejection fraction ( rEF ) were defined as baseline left ventricular ( LV ) ejection fraction values between 40% and 49% and P P <0.001) than rEF patients. Moreover, 29 out of 175 mr EF patients (17%) evolved to rEF . Restrictive LV filling pattern emerged as the strongest predictor of rEF development following multivariable analysis. Conclusions: mr EF identified a consistent subgroup of dilated cardiomyopathy patients diagnosed in an earlier stage with subsequent apparent better long‐term evolution. However, 17% of these patients evolved into rEF despite the use of medical therapy. A baseline restrictive LV filling pattern was independently associated with subsequent evolution to rEF .
- 3 September 2019
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 8 (17) , e010705
Open AccessDilated Cardiomyopathy With Mid‐Range Ejection Fraction at Diagnosis: Characterization and Natural History
Background: Limited data are available on mid‐range ejection fraction (mr EF ) patients with dilated cardiomyopathy. We sought to define the characteristics, evolution, and long‐term prognosis of dilated cardiomyopathy patients with mr EF at diagnosis. Methods and Results: We analyzed all dilated cardiomyopathy patients consecutively evaluated in the Trieste Heart Muscle Disease Registry from 1988 to 2013. mr EF and reduced ejection fraction ( rEF ) were defined as baseline left ventricular ( LV ) ejection fraction values between 40% and 49% and P P <0.001) than rEF patients. Moreover, 29 out of 175 mr EF patients (17%) evolved to rEF . Restrictive LV filling pattern emerged as the strongest predictor of rEF development following multivariable analysis. Conclusions: mr EF identified a consistent subgroup of dilated cardiomyopathy patients diagnosed in an earlier stage with subsequent apparent better long‐term evolution. However, 17% of these patients evolved into rEF despite the use of medical therapy. A baseline restrictive LV filling pattern was independently associated with subsequent evolution to rEF .
- Open Access
- 18 July 2019
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 21 (10) , 1294-1296
Prognostic Impact of Short-Term Changes of E/E' Ratio and Left Atrial Size in Dilated Cardiomyopathy
- 18 July 2019
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 21 (10) , 1294-1296
Open AccessPrognostic Impact of Short-Term Changes of E/E' Ratio and Left Atrial Size in Dilated Cardiomyopathy
- 1 May 2019
- Published by Wolters Kluwer Health in Journal of Cardiovascular Medicine
- Vol. 20 (5) , 343-350
Arrhythmic risk stratification in patients with dilated cardiomyopathy and intermediate left ventricular dysfunction
Aims: Arrhythmic risk stratification is a challenging issue in patients with dilated cardiomyopathy (DCM), particularly when left ventricular ejection fraction (LVEF) is more than 35%. We studied the prevalence and predictors of sudden cardiac death or malignant ventricular arrhythmias (SCD/MVAs) in DCM patients categorized at low arrhythmic risk because of intermediate left ventricular dysfunction under optimal medical treatment (OMT). Methods: DCM patients considered at low arrhythmic risk (LVEF >35% and New York Heart Association class I-III after 6 ± 3 months of OMT) were analysed. An arrhythmogenic profile was defined as the presence of at least one among a history of syncope, nonsustained ventricular tachycardia, at least 1000 premature ventricular contractions/24 h, at least 50 ventricular couplets/24 h at Holter ECG monitoring. SCD/MVAs was considered as the study end-point. Results: During a median follow-up of 152 months (interquartile range 100–234), 30 out of 360 (8.3%) patients at low arrhythmic risk (LVEF 47 ± 7%) experienced the study end-point [14 (3.9%) SCD and 16 (4.4%) MVA]. Compared with survivors, patients who experienced SCD/MVAs had more frequently an arrhythmogenic profile and a larger left atrium. Their LVEF at the last available evaluation before the arrhythmic event was 36 ± 12%. At multivariable analysis, left atrial end-systolic area [hazard ratio 1.107; 95% confidence interval (95% CI) 1.039–1.179, P = 0.002 for 1 mm2 increase] and arrhythmogenic profile (hazard ratio 3.667; 95% CI 1.762–7.632, P = 0.001) emerged as predictors of SCD/MVAs during follow-up. Conclusion: A consistent quota of DCM patients with intermediate left ventricular dysfunction receiving OMT experienced SCD/MVA during follow-up. Left atrial dilatation and arrhythmogenic pattern were associated with a higher risk of SCD/MVA.
- 1 May 2019
- Published by Wolters Kluwer Health in Journal of Cardiovascular Medicine
- Vol. 20 (5) , 343-350
Arrhythmic risk stratification in patients with dilated cardiomyopathy and intermediate left ventricular dysfunction
Aims: Arrhythmic risk stratification is a challenging issue in patients with dilated cardiomyopathy (DCM), particularly when left ventricular ejection fraction (LVEF) is more than 35%. We studied the prevalence and predictors of sudden cardiac death or malignant ventricular arrhythmias (SCD/MVAs) in DCM patients categorized at low arrhythmic risk because of intermediate left ventricular dysfunction under optimal medical treatment (OMT). Methods: DCM patients considered at low arrhythmic risk (LVEF >35% and New York Heart Association class I-III after 6 ± 3 months of OMT) were analysed. An arrhythmogenic profile was defined as the presence of at least one among a history of syncope, nonsustained ventricular tachycardia, at least 1000 premature ventricular contractions/24 h, at least 50 ventricular couplets/24 h at Holter ECG monitoring. SCD/MVAs was considered as the study end-point. Results: During a median follow-up of 152 months (interquartile range 100–234), 30 out of 360 (8.3%) patients at low arrhythmic risk (LVEF 47 ± 7%) experienced the study end-point [14 (3.9%) SCD and 16 (4.4%) MVA]. Compared with survivors, patients who experienced SCD/MVAs had more frequently an arrhythmogenic profile and a larger left atrium. Their LVEF at the last available evaluation before the arrhythmic event was 36 ± 12%. At multivariable analysis, left atrial end-systolic area [hazard ratio 1.107; 95% confidence interval (95% CI) 1.039–1.179, P = 0.002 for 1 mm2 increase] and arrhythmogenic profile (hazard ratio 3.667; 95% CI 1.762–7.632, P = 0.001) emerged as predictors of SCD/MVAs during follow-up. Conclusion: A consistent quota of DCM patients with intermediate left ventricular dysfunction receiving OMT experienced SCD/MVA during follow-up. Left atrial dilatation and arrhythmogenic pattern were associated with a higher risk of SCD/MVA.
- 1 March 2019
- Published by Elsevier in International Journal of Cardiology
- Vol. 278, 180-185
Left bundle branch block in dilated cardiomyopathy with intermediate left ventricular dysfunction: Clinical phenotyping and outcome correlates
- 1 March 2019
- Published by Elsevier in International Journal of Cardiology
- Vol. 278, 180-185
Left bundle branch block in dilated cardiomyopathy with intermediate left ventricular dysfunction: Clinical phenotyping and outcome correlates
Association between mutation status and left ventricular reverse remodelling in dilated cardiomyopathy
Objective: To explore the genetic landscape of a well selected dilated cardiomyopathy (DCM) cohort, assessing the possible relation between different genotypes and left ventricular reverse remodelling (LVRR). Methods: A cohort of 152 patients with DCM from the Heart Muscle Disease Registry of Trieste has been studied by next-generation sequencing (NGS). Patients were grouped into different ‘gene-clusters’ with functionally homogeneous genetic backgrounds. LVRR was defined by left ventricular ejection fraction normalisation or increase ≥10% associated with normalisation in indexed left ventricular end-diastolic diameter or relative decrease ≥10% at 24 months follow-up. Results: A pathogenic disease-related gene variant was identified in 57% of patients: 28 (18%) TTN; 7 (5%) LMNA; 16 (11%) structural cytoskeleton Z-disk genes; 9 (6%) desmosomal genes; 18 (12%) motor sarcomeric genes and 9 (6%) other genes. Baseline clinical features were similar throughout the different genotypes. A significant relationship was found between gene cluster subgroups and LVRR, with a lower rate of LVRR in structural cytoskeleton Z-disk gene mutation carriers (1/16 patients, 6%, pvs the other subgroups). Of note, structural cytoskeleton Z-disk gene rare variants were independently and inversely associated with LVRR when adjusted for clinical predictors of LVRR (OR 0.065; 95% CI 0.008 to 0.535, p=0.011). Conclusions: NGS confirmed a high genetic diagnostic yield in DCM. A specific ‘gene-clusters’ classification based on functional similarities in different genes might be helpful in the clinical management of genetically determined DCM. In this study, structural cytoskeleton Z-disk gene rare variants were independently associated with a lower rate of LVRR at follow-up.
Association between mutation status and left ventricular reverse remodelling in dilated cardiomyopathy
Objective: To explore the genetic landscape of a well selected dilated cardiomyopathy (DCM) cohort, assessing the possible relation between different genotypes and left ventricular reverse remodelling (LVRR). Methods: A cohort of 152 patients with DCM from the Heart Muscle Disease Registry of Trieste has been studied by next-generation sequencing (NGS). Patients were grouped into different ‘gene-clusters’ with functionally homogeneous genetic backgrounds. LVRR was defined by left ventricular ejection fraction normalisation or increase ≥10% associated with normalisation in indexed left ventricular end-diastolic diameter or relative decrease ≥10% at 24 months follow-up. Results: A pathogenic disease-related gene variant was identified in 57% of patients: 28 (18%) TTN; 7 (5%) LMNA; 16 (11%) structural cytoskeleton Z-disk genes; 9 (6%) desmosomal genes; 18 (12%) motor sarcomeric genes and 9 (6%) other genes. Baseline clinical features were similar throughout the different genotypes. A significant relationship was found between gene cluster subgroups and LVRR, with a lower rate of LVRR in structural cytoskeleton Z-disk gene mutation carriers (1/16 patients, 6%, pvs the other subgroups). Of note, structural cytoskeleton Z-disk gene rare variants were independently and inversely associated with LVRR when adjusted for clinical predictors of LVRR (OR 0.065; 95% CI 0.008 to 0.535, p=0.011). Conclusions: NGS confirmed a high genetic diagnostic yield in DCM. A specific ‘gene-clusters’ classification based on functional similarities in different genes might be helpful in the clinical management of genetically determined DCM. In this study, structural cytoskeleton Z-disk gene rare variants were independently associated with a lower rate of LVRR at follow-up.
- 1 February 2017
- Published by Elsevier in The American Journal of Cardiology
- Vol. 119 (3) , 483-489
Comparison of Patient Characteristics and Course of Hypertensive Hypokinetic Cardiomyopathy Versus Idiopathic Dilated Cardiomyopathy
- 1 February 2017
- Published by Elsevier in The American Journal of Cardiology
- Vol. 119 (3) , 483-489
Comparison of Patient Characteristics and Course of Hypertensive Hypokinetic Cardiomyopathy Versus Idiopathic Dilated Cardiomyopathy